Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24310936 | 1.00 | EPHX2 (0.40) | EPHX2RAB9ANPC1EPHX1KDM1A | |
| SCHEMBL22893113 | 1.00 | EPHX2 (0.40) | EPHX2RAB9ANPC1EPHX1KDM1A | |
| SCHEMBL22893117 | 1.00 | EPHX2 (0.40) | EPHX2RAB9ANPC1EPHX1KDM1A | |
| SCHEMBL18401356 | 1.00 | EPHX2 (0.40) | EPHX2RAB9ANPC1EPHX1KDM1A | |
| SCHEMBL22906294 | 1.00 | EPHX2 (0.40) | EPHX2RAB9ANPC1EPHX1KDM1A | |
| SCHEMBL10037070 | 0.98 | EPHX2 (0.37) | EPHX2RAB9ANPC1EPHX1KDM1A | |
| Iodide SCHEMBL2647139 | 0.96 | EPHX2 (0.36) | EPHX2RAB9ANPC1EPHX1KDM1A | |
| SCHEMBL5519016 | 0.89 | GBA1 (0.34) | SIGMAR1OPRM1OPRD1OPRK1 | |
| Bromide SCHEMBL28426746 | 0.87 | GBA1 (0.33) | SIGMAR1 | |
| SCHEMBL15593375 | 0.80 | ACHE (0.38) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-8796330-B2 | Inhibitors of histone deacetylase and prodrugs thereof | METHYLGENE INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| CN-101686665-B | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC | 2014-04-23 | — | — | CN | disclosed |
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2014-01-23 | — | — | US | disclosed |
| US-RE43343-E1 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-05-01 | — | — | US | disclosed |
| CN-101686665-A | styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC | 2010-03-31 | — | — | CN | disclosed |
| US-20090286863-A1 | SULFAMATOBENZOTHIOPHENE DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2009-11-19 | — | — | US | disclosed |
| US-20080146623-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-RE39850-E1 | Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents | METHYLGENE, INC. (CA) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | EPHX2 2127/4885RAB9A 2344/4885NPC1 3590/4885 |
| US-20080146623-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | HDAC1, HDAC3, HDAC11 | EPHX2 1251/4885RAB9A 2615/4885NPC1 787/4885 |
| US-20090286863-A1 | SULFAMATOBENZOTHIOPHENE DERIVATIVES | SULT1A1, SULT1E1, SULT2A1 | EPHX2 1074/4885RAB9A 4677/4885NPC1 4401/4885 |
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | HDAC1, HDAC3, HDAC11 | EPHX2 1251/4885RAB9A 2615/4885NPC1 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.